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Abstract
Aims: A recent study suggested that women with heart failure and heart failure reduced ejection fraction might
hypothetically need lower doses of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers
(¼ renin-angiotensin-system inhibitors) and b-blockers than men to achieve the best outcome. We assessed the current
medical treatment of heart failure reduced ejection fraction in men and women in a large contemporary cohort and
address the hypothetical impact of changing treatment levels in women.
Methods: This analysis is part of a large contemporary quality of heart failure care project which includes 5320 (64%)
men and 3003 (36%) women with heart failure reduced ejection fraction. Detailed information on heart failure therapy
prescription and dosage were collected.
Results: Women less often received renin-angiotensin-system inhibitors (79% vs 83%, p< 0.01), but more often
b-blockers (82% vs 79%, p< 0.01) than men. Differences in guideline-recommended target doses between sexes
were relatively small. Implementing a hypothetical sex-specific dosing schedule (at 50% of the current recommended
dose in the European Society of Cardiology guidelines in women only) would lead to significantly higher levels of women
receiving appropriate dosing (b-blocker 87% vs 54%, p< 0.01; renin-angiotensin-system inhibitor 96% vs 75%, p< 0.01).
Most interestingly, the total number of women with >100% of the new hypothetical target dose would be 24% for
b-blockers and 52% for renin-angiotensin-system inhibitors, which can be considered as relatively overdosed.
Conclusion: In this large contemporary heart failure registry, there were significant but relatively small differences in
drug dose between men and women with heart failure reduced ejection fraction. Implementation of the hypothetical
sex-specific target dosing schedule would lead to considerably more women adequately treated. In contrast, we iden-
tified a group of women who might have been relatively overdosed with increased risk of side-effects and intolerance.
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Introduction
The overall enrolment of women in clinical trials inves-
tigating treatment and outcome in heart failure (HF) is
generally low and, accordingly, women are underrep-
resented in these trials as compared to the real-world.1
Studies on optimal dose in HF with reduced ejection
fraction (HFrEF) are scarce and the number of includ-
ed women was low.2,3 Likewise, the European Society
of Cardiology (ESC) HF guidelines provide no sex-
specific recommendations.4 Recently, the hypothesis
has been suggested that women with HFrEF might
need lower dose of angiotensin-converting enzyme
inhibitors (ACE-is), angiotensin II receptor blockers
(ARBs) and b-blockers than men, which brings into
question what the true optimal level of drug therapy
is for women.5 Whereas men obtained the maximal
reduction of mortality and HF hospitalization at the
guideline recommended target dose of b-blockers,
ACE-Is and ARBs. In male HFrEF patients, not
achieving target dose is equal to not achieving maxi-
mum treatment benefit.
In contrast, in women the largest treatment benefit
was already observed at 50% of recommended target
dose, achieving 30% lower overall cardiovascular risk
(all-cause mortality or hospitalization for HF). At
higher doses, no additional benefit was observed in
women, therefore the hypothesis is that maximum ben-
efit can be achieved at 50% of target dose at no further
expense of intolerance of side-effects.5 The clinical
impact of this post-hoc analysis can be considerable
but should be assessed in large contemporary HFrEF
cohorts.
The Chronisch Hartfalen ESC-richtlijn
Cardiologische praktijk Kwaliteitsproject HartFalen
(CHECK-HF) registry is a large scale (n¼ 8323) con-
temporary and well defined Dutch cohort of HFrEF
patients,6,7 enabling us to assess the impact of adopting
the hypothetical sex-specific dose schedule in a real-
world outpatient setting.
Methods
The design and methods of the CHECK-HF registry
have been published in detail earlier.6,7 Briefly, the
CHECK-HF study is a large contemporary cross-
sectional observational cohort, including a total of
10,910 chronic HF patients from 34 participating
Dutch centres between September 2013–September
2016. All patients were diagnosed and treated accord-
ing to the 2012 ESC HF guidelines,8 and almost all
were seen at a dedicated outpatient HF clinic (96%).
Detailed information on patient characteristics, echo-
cardiographic parameters and HF therapy, including
HF drug prescription, dose, contraindication and
intolerance, as well as device therapy were recorded.
This study was conducted according to the Helsinki
Declaration, and was approved by the medical ethics
committee in 2017 at the Maastricht University
Medical Center (Maastricht, the Netherlands).
Patients were not involved in the research process.
Left ventricular function, assessed during the most
recent outpatient clinical visit, was used to categorise
HF patients. Patients were categorised based on left
ventricle ejection fraction (LVEF) or visual assessment
of left ventricle (LV) function into HFrEF
(LVEF<50% (n¼ 8360 (76.6%)) and HF with pre-
served ejection fraction (HFpEF) (LVEF50%
(n¼ 2267 (20.8%)). In 283 patients, recording of LV
function in the database was insufficient to classify
patients into HF type. In addition, standard baseline
demographic data was missing in 37 additional HFrEF
patients, leaving 8323 HFrEF patients to be included in
the analysis.
For a sub-analysis according to the newer 2016 ESC
HF guidelines,4 patients with an assessed LVEF<50%
were categorised into HF with mid-range ejection frac-
tion (HFmrEF) (LVEF 40–49% (n¼ 1571 (18.9%))
and HFrEF (LVEF<40% (n¼ 5677 (68.2%), only in
those patients with a exactly specified LVEF or into
patients with only a semi-quantitative analysis of LV
function (n¼ 1075 (12.9%)).
In order to investigate the impact of the hypothetical
sex-specific dose schedule of b-blockers and renin-
angiotensin-system inhibitors (RAS-is) (i.e. ACE-is or
ARBs), we analysed the prescribed dosages expressed
as a percentage of the recommended target dose and of
the hypothetical target dosage (50% of the guideline
recommend target dose) in women. Target doses of
guideline-recommended HF therapy are presented in
Supplementary Material Table 1 and in line with the
ESC HF guidelines.4
Statistical analysis
Continuous data are expressed as mean value
 standard deviation (SD) or median and interquartile
range, depending on the distribution of the data, and
compared by one-way analyses of variance (ANOVAs)
or Mann-Whitney U-test. Categorical data are
expressed as counts and percentages, and compared
by the Pearson Chi-square test. The prescribed dosages
are expressed as a percentage of the recommended
target dose. The differences between the recommended
and newly suggested target dose were compared by the
McNemar test.
Multivariable predictors of HF medication use were
assessed using multivariable logistic regression analy-
sis. All predictors of medication use in univariable
analysis at a p-value of <0.10 were included in a
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forward step manner in the multivariable logistic
regression analysis. Results of logistic regression are
presented as odds ratio (ORs) with 95% confidence
intervals (CIs).
For variables with missing data in the multivariable
analysis, we used multiple imputation modelling. If the
missing variables showed a monotone pattern of miss-
ing values, the monotone method was used, otherwise,
an iterative Markov chain Monte Carlo method was
used with a number of 10 iterations. A total of five
imputations was performed, and the pooled data were
analysed. All analyses were performed with SPSS
Statistical Package version 25.0 (SPSS Inc., Chicago,
Illinois, USA).
Results
Baseline characteristics of men and women with
HFrEF are presented in Table 1.
Pharmacological therapy in HFrEF
Female HFrEF patients significantly less often received a
RAS-i (78.9% vs 82.6%, p< 0.01) and more often
b-blockers (82.0% vs 79.1%, p< 0.01), ivabradine
(5.2% vs 4.2%, p¼ 0.04) and diuretics (85.0% vs
81.6%, p< 0.01) compared to male HFrEF patients
(Figure 1(a)). Of the women that received a RAS-i, a
significantly lower percentage received the guideline-
recommended target dose (74.8% vs 76.1%, p¼ 0.01)
as compared to men (Figure 1(b)). Triple HF therapy,
consisting of b-blocker, RAS-i and mineralocorticoid
receptor antagonist (MRA) (at indication), as well as
triple therapy prescribed at 50% of the guideline-
recommended target dose, were equally prescribed in
women and men (Figure 1(c) and (d)). No sex-specific
significant differences in the number of reported contra-
indications or intolerances were observed, although the
numbers of contraindications and intolerances were very
low in both groups (Supplementary Material Table 2).
Table 1. Patient characteristics in heart failure with reduced ejection fraction (HFrEF) patients.
Men (n¼ 5320) Women (n¼ 3003) p-Value
Age (years) (n¼ 8314) 71.6 11.4 73.4 12.4 <0.01
BMI, kg/m2 (n¼ 7638) 27.3 4.8 27.1 5.8 0.32
NYHA (n¼ 8226)
I 913 (17.4) 395 (13.3) <0.01
II 3000 (57.1) 1671 (56.2)
III 1248 (23.8) 850 (28.6)
IV 90 (1.7) 59 (2.0)
LVEF, % (n¼ 6154) 32.2 10.4 33.5 10.8 <0.01
Cause of HF (n¼ 8058)
Ischaemic 3016 (58.5) 1149 (39.6) <0.01
Non-ischaemic 2137 (41.5) 1756 (60.4)
Systolic BP, mm Hg (n¼ 8209) 125.3 20.5 126.4 21.0 0.02
Diastolic BP, mm Hg (n¼ 8215) 71.5 11.3 70.7 11.4 <0.01
Heart rate, bpm (n¼ 8211) 71.2 13.7 73.5 14.0 <0.01
Atrial fibrillation (n¼ 8216) 1366 (26.0) 734 (24.8) 0.25
LBBB (n¼ 8323) 838 (15.8) 574 (19.1) <0.01
QRS 130 ms (n¼ 6908) 1877 (42.5) 887 (35.7) <0.01
eGFR (n¼ 5883) 61.4 24.8 56.6 24.0 <0.01
eGFR (n¼ 5883)
<30 364 (9.8) 303 (14.0) <0.01
30–59 1510 (40.6) 932 (43.0)
60 1844 (49.6) 930 (43.0)
Comorbidities (n¼ 7459)
Hypertension 1801 (37.9) 1168 (43.2) <0.01
Diabetes mellitus 1380 (29.0) 789 (29.2) 0.87
COPD 904 (19.0) 466 (17.2) 0.06
OSAS 401 (8.4) 92 (3.4) <0.01
Thyroid disease 257 (5.4) 300 (11.1) <0.01
BMI: body mass index; BP: blood pressure; COPD: chronic obstructive pulmonary disease; eGFR: estimated glomerular filtration rate;
HF: heart failure; LBBB: Left Bundle Branch Block; LVEF: left ventricular ejection fraction; NYHA: New York Heart Association; OSAS:
obstructive sleeping apnoea syndrome.
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Figure 1. (a) Heart failure (HF) therapy usages; (b) prescribed dosages expressed as a percentage of recommended target dose;
(c) triple therapy prescribed; and (d) triple therapy at 50% of the recommended target dose prescribed in men and women.
RAS-i: renin-angiotensin-system inhibitor; MRA: mineralocorticoid receptor antagonist.
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Predictors of prescription and target dose of
HF therapy
In the multivariable regression analysis, lower age and
the presence of hypertension were significant predictors
of prescription of b-blockers; lower age, male gender
and renal insufficiency were significant predictors of
prescription of a RAS-i; and lower age, higher New
York Heart Association (NYHA)-classification and
lower systolic blood pressure were significant predic-
tors of prescription of MRAs (Table 2). In multivariate
analysis, the chance of receiving the guideline-
recommended target dose of a RAS-i was independent-
ly related to male gender, while the chance of receiving
the guideline-recommended target dose of MRA was
independently related to female gender (Table 3).
Multiple imputations did not change the results (data
not shown).
Clinical impact of new hypothetical sex-specific
target dose schedule
Using the hypothetical sex-specific target doses (at 50%
of the current recommended dose in the ESC guidelines
in women only), leads to an considerable increase in the
number of women who received the target dose for
b-blockers (87.2% vs 53.6%, p< 0.01) and RAS-is
(96.0% vs 74.8%, p< 0.01) (Figure 2(a)). A large
number of women might be relatively overdosed,
23.5% of women received >100% of the hypothetical
target dose for b-blockers and 52.1% for RAS-is, in
our study. A significant increase in women receiving
both HF drugs (with indication) at 50% of the new
hypothetical target dose (56.3% vs 29.5%, p< 0.01)
was observed (Figure 2(b)).
Analysis in patients with HFmrEF according to 2016
ESC guidelines
A sub-analysis studying the different cut-off of
HFmrEF and HFrEF according to the ESC 2016
guidelines does not change the inferences of this anal-
ysis (Supplementary Material Table 3, Supplementary
Material Figure 1). Likewise, the subgroup of semi-
quantitative LV function showed similar differences
(Supplementary Material Figure 1).
Table 2. Multivariable predictors of the use of heart failure (HF) therapy in heart failure with reduced ejection fraction (HFrEF)
patients in relation to gender.
b-Blocker RAS-i MRA Ivabradine Diuretics
Univariable Gender 1.20 (1.07–1.35) 0.79 (0.70–0.88) 1.02 (0.93–1.11) 1.24 (1.01–1.53) 1.28 (1.13–1.45)
Multivariable Gender 1.16 (0.99–1.36) 0.82 (0.70–0.97) 1.11 (0.99–1.23) 1.29 (1.04–1.60) 1.30 (1.07–1.58)
Age (per 10 years
increase)
0.84 (0.79–0.90) 0.78 (0.72–0.85) 0.91 (0.87–0.95) 0.66 (0.61–0.72) 1.22 (1.12–1.33)
BMI – 1.03 (1.01–1.05) 1.02 (1.01–1.03) – 1.06 (1.04–1.08)
LVEF – 0.99 (0.98–0.99) 0.99 (0.99–0.99) 0.98 (0.97–0.99) –
NYHA classification – 0.76 (0.67–0.86) 1.32 (1.22–1.42) 1.44 (1.23–1.69) 1.66 (1.43–1.92)
Ischaemic aetiology HF – – – – –
Systolic blood pressure
(per 10 mm Hg
increase)
– – 0.83 (0.80–0.85) – 0.92 (0.86–0.97)
Diastolic blood pres-
sure (per 10 mm Hg
increase)
– – – 0.80 (0.73–0.88) 0.85 (0.77–0.94)
Heart rate (per 10
beats/min increase)
– 0.86 (0.81–0.91) 0.96 (0.93–1.00) – 1.14 (1.06–1.22)
QRS duration (per 10
ms increase)
– 0.96 (0.94–0.99) 1.03 (1.01–1.05) – 1.03 (1.01–1.06)
eGFR (per 10 ml/min
increase)
– 1.08 (1.04–1.12) – – 0.67 (0.83–0.90)
Hypertension 1.26 (1.08–1.46) – – 0.60 (0.37–0.96) –
Diabetes mellitus – – – 1.61 (1.29–2.00) 1.37 (1.11–1.70)
COPD – – – 1.70 (1.33–2.16) –
BMI: body mass index; COPD: chronic obstructive pulmonary disease; eGFR: estimated glomerular filtration rate; LVEF: left ventricular ejection
fraction; MRA: mineralocorticoid receptor antagonist; NYHA: New York Heart Association.
This table shows the results from the univariable logistic regression analysis, demonstrating the likelihood of using HF therapy in women over men.
Additionally, it demonstrates the likelihood of using HF therapy in women over men adjusted in the full multivariable model.- indicates variable not
included in the model.
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Discussion
The current analysis shows that HF treatment between
men and women differs in this large real-world contem-
porary cohort of HFrEF patients. Women received
lower doses of HF drugs compared to men. The level
of the target dose of HF drugs or maximally tolerated
levels has been frequently discussed and recently gained
more attention from a study suggesting that the opti-
mal dose level might be 50% lower in women com-
pared with men at maximum sex-specific treatment
benefit.5 This hypothesis has major implications for
HF treatments in general, and we assessed the impact
of this new hypothetical dose schedule in women.
In this patient sample, doctors were urged to titrate
to guideline-recommended dosages, and this was suc-
cessful in some, but not all, patients.
In male patients with HFrEF, the post-hoc analysis
from BIOlogy Study to TAilored Treatment in Chronic
Heart Failure (BIOSTAT-CHF) shows that male
patients only achieve maximum treatment benefit at
the full recommended target dose of HF medication.
In women, the maximum treatment benefit was
observed at 50% of the target dose with no further
gain in benefit, with only futile risk of intolerance.
Naturally, if lower dosages were accepted as ‘optimal’
in females, a much larger proportion of the female
patients would be regarded as being treated optimally
when 50% of the recommended dose would be
regarded as optimal. Notably, this approach identifies
a potential subgroup of women who are relatively over-
dosed (>100% dose in females) with an increased risk
of side effects and intolerance at no incremental benefit
of treatment.
Guideline adherence and sex
Women with a (non-ST-segment elevation) myocardial
infarction receive the guideline-recommended therapy
less often.9,10 Additionally, sex-specific treatment strat-
egies for these conditions have been proposed previous-
ly.10,11 Similarly, multiple registries have demonstrated
sex-related differences in guideline adherence, with
women less often receiving b-blockers,12 ACE-is,12–14
MRAs12 and more often ARBs15 and diuretics.1,12
The current results of our analysis are in line with
these previous registries, although sex-specific differen-
ces particularly regarding guideline-recommended
target doses were relatively small in CHECK-HF.
Differences in patient characteristics could influence
clinicians in their decision-making, but these differen-
ces do not fully explain the sex-related differences in
HF drug usage and dosages in our dataset.
Optimal doses of HF therapies in men versus women
Women are underrepresented in clinical trials investi-
gating the efficacy of HF drugs, as only 10–40% of the
Table 3. Multivariable predictors of receiving guideline-recommended target dose of HF medication in HFrEF patients in relation to
gender.
b-Blocker RAS-i MRA
Univariable Gender 1.03 (0.90–1.17) 0.88 (0.80–0.98) 1.35 (1.19–1.52)
Multivariable Gender 1.00 (0.83–1.22) 0.87 (0.76–0.99) 1.34 (1.01–1.11)
Age (per 10 years increase) 0.87 (0.80–0.94) 0.86 (0.81–0.91) –
BMI 1.02 (1.00–1.04) 1.03 (1.02–1.04) 1.03 (1.01–1.12)
LVEF – – –
NYHA classification – 0.81 (0.73–0.90) –
Ischaemic aetiology HF 0.81 (0.67–0.98) – –
Systolic blood pressure (per
10mm Hg increase)
– 1.24 (1.20–1.29) 0.91 (0.88–0.95)
Diastolic blood pressure (per
10mm Hg increase)
1.19 (1.09–1.29) – –
Heart rate (per 10 beats/min
increase)
– 0.95 (0.91–1.00) 1.06 (1.01–1.11)
QRS duration (per 10 ms
increase)
– – 1.03 (1.01–1.05)
eGFR (per 10 ml/min increase) – – –
Hypertension 1.33 (1.10–1.60) 1.38 (1.21–1.58) –
Diabetes mellitus 1.30 (1.06–1.59) – 1.17 (1.00–1.36)
BMI: body mass index; COPD: chronic obstructive pulmonary disease; eGFR: estimated glomerular filtration rate; HF: heart failure; LVEF: left
ventricular ejection fraction; MRA: mineralocorticoid receptor antagonist; NYHA: New York Heart Association.
This table shows the results from the univariable logistic regression analysis, demonstrating the likelihood of prescribing the guideline-recommended
target dose of HF drugs in women over men. Additionally, it demonstrates the likelihood of prescribing the guideline-recommended target dose of HF
drugs in women over men adjusted in the full multivariable model. - indicates variable not included in the model.
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patients included in these trials were women.16
Furthermore, only one trial investigated efficacy pro-
spectively stratified by sex,17 while all other studies
analysed sex-related effects retrospectively and in
post-hoc analyses, limiting these results. In women,
the use of ACE-is leads to a non-significant reduction
in all-cause mortality and hospitalizations compared to
placebo.18 The use of ARBs reduced all-cause mortality
and hospitalizations in women compared to placebo.19
Women using b-blockers had a better clinical outcome
compared to women receiving placebo therapy,20–22
and similar favourable treatment effects were seen in
women using MRAs.23,24 Studies investigating the ideal
target dose in HFrEF are scarce, especially in
women,2,3 therefore a one-size-fits-all strategy is recom-
mended in the ESC HF guidelines.4
Several sex-related pharmacological differences can
cause differences in the efficacy of HF drugs between
men and women. So differences in body weight, med-
ication clearance rate and the effect of sex hormones
contribute to higher plasma concentrations, and stron-
ger effects of HF drugs in women.25,26 Additionally, it
has been suggested that HF drugs might have a larger
effect in women compared to men, even if the plasma
concentrations are similar.27
HF therapy dose and sex
Data on the ideal dosages in women are scarce. Two
post-hoc analyses from the Heart failure Endpoint
evaluation of Angiotensin II Antagonist Losartan
(HEAAL) and Assessment of Treatment with
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Figure 2. Impact of the newly proposed sex-specific target dose strategy (a) prescribed dosages expressed as a percentage of the
guideline and newly proposed target dose of b-blockers and renin-angiotensin-system inhibitors (RAS-is), and (b) dual therapy at
50% of the guideline and newly proposed target dose prescribed in women.
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Lisinopril and Survival (ATLAS) trials demonstrated
that a lower RAS-i dosage in women was equally effec-
tive, or even more effective, compared to higher dos-
ages.2,28 In contrast, higher dosages of RAS-is were
more effective in men. These results suggest that
using a one-size-fits-all target dose could lead to over-
dosing in women. A sub-analysis from these trials
investigating the potential overdosing and its effect
would be of great interest, especially since a post-hoc
analysis from the Digitalis Investigation Group (DIG)
trial demonstrated that women had a higher serum
concentration compared to men, although they used a
slightly lower dose adjusted for body-mass index.29,30 A
similar effect has been seen in the use of b-blockers,
with women having a higher serum concentration
while using a similar dosage.25
New hypothetical target dose levels in women
Recently, a post-hoc analysis from the BIOSTAT-CHF
study investigated whether sex-related differences in the
optimal dose of b-blockers and RAS-is for preventing
all-cause mortality and HF-related hospitalization
exists in HFrEF patients, and validated the results in
the Asian Sudden Cardiac Death in Heart Failure
(ASIAN-HF) dataset.5 This post-hoc analysis demon-
strated that in women a 30% risk reduction in all-cause
mortality and HF-related hospitalizations can be
obtained with approximately 50% of the recommended
target dose of b-blockers and RAS-is, with no further
decrease in risk at higher dose levels in BIOSTAT-CHF
and ASIAN-HF validation cohorts. In contrast, in men
the largest reduction was observed if 100% of the rec-
ommended target dose was reached. These results sug-
gest that women with HFrEF might have similar
clinical outcomes with lower doses of b-blockers and
RAS-is than recommended in the ESC HF guidelines.4
Naturally, if lower target doses were accepted as opti-
mal in women, a larger proportion of women would be
regarded as treated optimally, in our registry.
Additionally, we identified a large group of women
who were potentially overdosed, possibly without an
incremental benefit. It is generally believed that
women are more often affected by drug-related adverse
effects31–33 and differences in target doses could be an
explanation for this. Unfortunately, we do not have
adequate data on side-effects to support this statement
from our study. In these women, the doses might be
lowered, improving patient compliance and lowering
intolerance rates.
Similar to these findings, specific guideline recom-
mendations or target dosages might be warranted for
different subgroups as well, for example specific guide-
lines for races or body mass index (BMI) category.
However, these should be evaluated by additional
research.
Limitations and strengths
Our study has some limitations. CHECK-HF has a
cross-sectional design with no follow-up data on
patient outcomes. Other prospective studies integrating
dose findings of HF therapy in women and outcome
are needed. Still, our analysis shows the potentially
large impact of the newly proposed target levels. In
addition, for some variables a limited number of data
were missing, however, after using multiple imputation
this did not impact the results. Additionally, with
changing HF categories based on LVEF in the newer
guidelines,4 our analysis was limited by a small number
of patients where LV function was semi-quantitatively
analysed with echocardiography. Strengths of the
CHECK-HF registry include the large scale, contem-
porary (2016), and a reflection of the real-world prac-
tice of outpatient HF management in the Netherlands,
representative of Western European countries.
Furthermore, the availability of a large number of
women with detailed information on medication pre-
scription and dosage is important due to the lack of
data in this subgroup, as previously noted.
Conclusion
In this large contemporary registry, drug dose signifi-
cantly differed between men and women with HFrEF,
although the differences where relatively small. As the
first large HF study, we demonstrate the clinical impact
of a hypothetical adjustment to a lower target dose
schedule in women, by which more women would be
considered adequately treated. On top of better adher-
ence, this identifies a considerable large subgroup of
women who are relatively overdosed in HF medication
at no further reduction in CV risk but, rather, at higher
risk of intolerance when the dose could have been fur-
ther reduced.
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